Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD
Arch Bronconeumol. 2025 Dec;61(12):766-782.
doi: 10.1016/j.arbres.2025.10.008.
Epub 2025 Oct 14.
[Article in
English,
Spanish]
Authors
Marc Miravitlles
1
, Myriam Calle
2
, Jesús Molina
3
, Pere Almagro
4
, José-Tomás Gómez
5
, Juan Antonio Trigueros
6
, Efraín Sánchez-Angarita
7
, Borja G Cosío
8
, Ciro Casanova
9
, José Luis López-Campos
10
, Juan Antonio Riesco
11
, Pere Simonet
12
, David Rigau
13
, Ainel Iskakova
13
, Mariano Pastor Sanz
14
, Patricia Sobradillo
15
, Bernardino Alcázar-Navarrete
16
, Noé Garin
17
, Juan José Soler-Cataluña
18
Affiliations
- 1 Servicio de Neumología, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Spain. Electronic address: marcm@separ.es.
- 2 CIBER de Enfermedades Respiratorias (CIBERES), Spain; Servicio de Neumología, Hospital Clínico San Carlos, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
- 3 Centro de Salud Francia, Dirección Asistencial Oeste, Grupo de Respiratorio de semFYC, Madrid, Spain.
- 4 Servicio de Medicina Interna, Hospital Universitario Mutua de Terrassa, Spain.
- 5 Centro de Salud de Nájera, La Rioja, Spain.
- 6 Centro de Salud de Buenavista, Toledo, Spain.
- 7 Servicio de Neumología, Omni Hospital Guayaquil, Guayas, Ecuador, Departamento de EPOC Asociación Latinoamericana del Tórax (ALAT), Spain.
- 8 CIBER de Enfermedades Respiratorias (CIBERES), Spain; Servicio de Neumología, Hospital Universitario Son Espases-IdISBa, Spain.
- 9 Servicio de Neumología-Unidad de Investigación Hospital Universitario Nuestra Señora de La Candelaria, Universidad de La Laguna, Tenerife, Spain.
- 10 CIBER de Enfermedades Respiratorias (CIBERES), Spain; Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Spain.
- 11 CIBER de Enfermedades Respiratorias (CIBERES), Spain; Servicio de Neumología, Hospital San Pedro de Alcántara, Cáceres, Spain.
- 12 Centro de Salud Viladecans-2, Gerència d'Atenció Primària i a la Comunitat Delta-Institut Català de la Salut, Barcelona, Spain; Departament de Ciències Clíniques, Universitat Barcelona, Barcelona, Spain.
- 13 Asociación Colaboración Cochrane Iberoamérica (ACCIb), Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
- 14 Presidente de la Federación Española de Asociaciones de Pacientes Alérgicos y con Enfermedades Respiratorias (FENAER) y vocal de la Junta Directiva del Foro Español de Pacientes (FEP), Spain.
- 15 Servicio de Neumología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain.
- 16 CIBER de Enfermedades Respiratorias (CIBERES), Spain; Servicio de Neumología, Hospital Universitario Virgen de las Nieves, Departamento de Medicina, Universidad de Granada, Instituto de Investigación Biosanitaria Ibs Granada, Granada, Spain.
- 17 Servicio de Farmacia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- 18 Servicio de Neumología, Hospital Arnau de Vilanova-Lliria, Departamento de Medicina, Universidad de Valencia, Valencia, Spain.
Abstract
The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since then, several updates have incorporated new evidence regarding the diagnosis and treatment of COPD. GesEPOC is a clinical practice guideline developed with the collaboration of the scientific societies involved in COPD management and the Spanish Patients' Forum. Its recommendations are based on an evaluation of the evidence using the GRADE methodology and on a narrative description of the evidence in those areas where application of this methodology is not feasible. This article summarizes the updated recommendations on the pharmacological treatment of stable COPD, derived from the development of 12 PICO questions. The COPD treatment process comprises five stages: (1) diagnosis; (2) risk stratification; (3) characterization; (4) initiation and continuation of treatment; and (5) follow-up. For inhaled treatment selection, high-risk patients are classified into three phenotypes: non-exacerbator, eosinophilic exacerbator, and non-eosinophilic exacerbator. Treatable traits include general aspects, applicable to all patients-such as smoking cessation and inhaler technique-and more specific conditions, mainly affecting severe patients, such as chronic hypoxemia or chronic bronchial infection. The cornerstone of COPD treatment is long-acting bronchodilators, either as monotherapy or in combination, depending on the patient's risk level. Eosinophilic exacerbators should receive inhaled corticosteroids, whereas non-eosinophilic exacerbators require a detailed evaluation to identify the most appropriate therapeutic option. GesEPOC 2025 also includes recommendations on inhaled corticosteroid withdrawal, the introduction of biologics, and the indication for alpha-1 antitrypsin therapy. GesEPOC 2025 represents a more individualized approach to COPD treatment, tailored to the clinical characteristics of patients and their level of risk or complexity.
Keywords:
COPD; Control; Guidelines; Phenotypes; Treatment.
Copyright © 2025 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Administration, Inhalation
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / therapeutic use
-
Bronchodilator Agents / administration & dosage
-
Bronchodilator Agents / therapeutic use
-
Humans
-
Pulmonary Disease, Chronic Obstructive* / diagnosis
-
Pulmonary Disease, Chronic Obstructive* / drug therapy
-
Spain
Substances
-
Bronchodilator Agents
-
Adrenal Cortex Hormones